Estamos teniendo problemas temporales. Actualmente los datos de mercado de esta página se están retrasando. Ten paciencia mientras lo solucionamos y restauramos tus listas personalizadas.
FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced a collaboration with Optibrium, a leading developer of software and artificial intelligence (AI) solutions for small molecule discovery. The agreement is part of FMC's strategic plan to accelerate the discovery and commercialization of FMC's pipeline.
Boots Capital Management, LLC ("Boots Capital"), an investment vehicle led by Ted B. Miller, co-founder and former Chief Executive Officer of Crown Castle Inc., (NYSE: CCI) ("Crown Castle" or the "Company"), today announced that Glass Lewis & Co. ("Glass Lewis"), a leading independent proxy advisory firm, has recommended that Crown Castle shareholders vote on Boots Capital's GOLD proxy card "FOR" the election of Boots Capital nominees Ted B. Miller and Charles C. Green, and "WITHOLD" from Crown
4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) ("4Front" or the "Company"), a vertically integrated multi-state cannabis operator and retailer, will report its financial and operating results for the first quarter ended March 31, 2024, on Friday, May 17, 2024, before the market opens. The Company will host a conference call to discuss the results and provide an update on current business trends on May 17, 2024, at 8:30 a.m. Eastern Time.
Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q 2024Use of proceeds from recent capital raise further advances plans for first patient enrollment in MDG1015 Phase 1 dose escalation trial by end of 2024, subject to additional financing Planegg/Martinsried, May 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-onco
Welcomes clients and members to its best-in-class platformDRAPER, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity"), the leader in Health Savings Account (HSA) and consumer-directed benefits administration, is pleased to announce the completed transfer of Conduent’s (Nasdaq: CNDT) BenefitWallet HSA portfolio. HealthEquity Chief Executive Officer, Jon Kessler said, "We are thrilled to welcome BenefitWallet clients and members as partners on our mission to sa
Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the publication of a patient-focused global consensus statement – 'Time to Act: A Global Patient-Focused Consensus for Improving the Care of Cutaneous T-Cell Lymphoma (CTCL)'.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (OTCQB: UDOCF) ("UniDoc," or the "Company"), an innovator in the eHealth sector, is pleased to announce the expansion of its existing AI partnership with DocBox Inc., further integrating advanced monitoring and predictive analytics into emergency room (ER) operations. This enhancement focuses on optimizing care for non-urgent ER visitors to improve efficiency and patient outcomes.
Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compoundsDURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Tavros Therapeutics, Inc., a precision oncology platform company, today announced that the Company has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG. The payments were triggered by the successful achieve
Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the first quarter ended March 31, 2024.